BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J Gastroenterol 2019; 25(14): 1684-1696 [PMID: 31011254 DOI: 10.3748/wjg.v25.i14.1684]
URL: https://www.wjgnet.com/1007-9327/full/v25/i14/1684.htm
Number Citing Articles
1
Guanghui Xu, Yuhao Wang, Hushan Zhang, Xueke She, Jianjun Yang. Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasiaFuture Oncology 2021; 17(9): 1069 doi: 10.2217/fon-2020-0703
2
Caroline Lum, Sophia Frentzas. Research and Clinical Applications of Targeting Gastric Neoplasms2021; : 317 doi: 10.1016/B978-0-323-85563-1.00010-1
3
Shuaishuai Xu, Chanqi Ye, Ruyin Chen, Qiong Li, Jian Ruan. The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine NeoplasmsCancers 2022; 14(12): 2911 doi: 10.3390/cancers14122911
4
Erik Rösner, Daniel Kaemmerer, Jörg Sänger, Amelie Lupp. Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological dataTranslational Oncology 2022; 25: 101526 doi: 10.1016/j.tranon.2022.101526
5
Alexander W. MacFarlane, Ho-Man Yeung, R. Katherine Alpaugh, Essel Dulaimi, Paul F. Engstrom, Arvind Dasari, Kerry S. Campbell, Namrata Vijayvergia. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasmsCancer Immunology, Immunotherapy 2021; 70(7): 1893 doi: 10.1007/s00262-020-02811-5
6
Z Liu, F Mi, M Han, M Tian, L Deng, N Meng, J Luo, R Fu. Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myelomaClinical and Experimental Immunology 2021; 205(1): 53 doi: 10.1111/cei.13594
7
Dong-Bing Zhao, He Fei, Tong-Bo Wang, Xiao-Feng Bai, Ying-Tai Chen, Hai-Zhen Lu, Ze-Feng Li. Mixed large and small cell neuroendocrine carcinoma of the stomach: A case report and review of literatureWorld Journal of Clinical Cases 2022; 10(16): 5502-5509 doi: 10.12998/wjcc.v10.i16.5502
8
Jiazhang Xing, Hongyan Ying, Ji Li, Yang Gao, Zhao Sun, Jiarui Li, Chunmei Bai, Yuejuan Cheng, Huanwen Wu. Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive SystemFrontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00132
9
Ilaria Maggio, Lisa Manuzzi, Giuseppe Lamberti, Angela Dalia Ricci, Nastassja Tober, Davide Campana. Landscape and Future Perspectives of Immunotherapy in Neuroendocrine NeoplasiaCancers 2020; 12(4): 832 doi: 10.3390/cancers12040832
10
Satoshi Yamashita, Hiroyuki Abe, Akiko Kunita, Hiroharu Yamashita, Yasuyuki Seto, Tetsuo Ushiku. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinomaHistopathology 2021; 78(3): 381 doi: 10.1111/his.14230
11
Virginia Corbett, Susanne Arnold, Lowell Anthony, Aman Chauhan. Management of Large Cell Neuroendocrine CarcinomaFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.653162
12
Mengyuan Liu, Elizabeta C. Popa, Brendan M. Finnerty, Thomas J. Fahey, Rasa Zarnegar. Clinicopathological Features of Gastroesophageal Neuroendocrine NeoplasmsCurrent Gastroenterology Reports 2020; 22(10) doi: 10.1007/s11894-020-00788-w
13
Chunyan Hu, Shu Tian, Lan Lin, Jiahao Zhang, Hao Ding. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinomaOral Oncology 2020; 102: 104560 doi: 10.1016/j.oraloncology.2019.104560
14
Klaire Exarchou, Nathan A. Stephens, Andrew R. Moore, Nathan R. Howes, D. Mark Pritchard. New Developments in Gastric Neuroendocrine NeoplasmsCurrent Oncology Reports 2022; 24(1): 77 doi: 10.1007/s11912-021-01175-y
15
Krzysztof Kaliszewski, Maksymilian Ludwig, Maria Greniuk, Agnieszka Mikuła, Karol Zagórski, Jerzy Rudnicki. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)Cancers 2022; 14(8): 2028 doi: 10.3390/cancers14082028
16
Wei Liu, Lei Zhang, Zhiming Xiu, Jian Guo, Liye Wang, Yue Zhou, Yang Jiao, Meiyan Sun, Jianhui Cai. <p>Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer</p>OncoTargets and Therapy 2020; : 7229 doi: 10.2147/OTT.S255491
17
Anja Rinke, Christoph J Auernhammer, Lisa Bodei, Mark Kidd, Sebastian Krug, Rita Lawlor, Ilaria Marinoni, Aurel Perren, Aldo Scarpa, Halfdan Sorbye, Marianne Ellen Pavel, Matthias M Weber, Irvin Modlin, Thomas M Gress. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?Gut 2021; 70(9): 1768 doi: 10.1136/gutjnl-2020-321300
18
Michele Prisciandaro, Maria Antista, Alessandra Raimondi, Francesca Corti, Federica Morano, Giovanni Centonze, Giovanna Sabella, Alessandro Mangogna, Giovanni Randon, Filippo Pagani, Natalie Prinzi, Monica Niger, Salvatore Corallo, Erica Castiglioni di Caronno, Marco Massafra, Maria Di Bartolomeo, Filippo de Braud, Massimo Milione, Sara Pusceddu. Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future PerspectiveFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.780716
19
Ioana Rada Popa Ilie, Carmen Emanuela Georgescu. Immunotherapy in Gastroenteropancreatic Neuroendocrine NeoplasiaNeuroendocrinology 2021;  doi: 10.1159/000518106
20
Melissa Frizziero, Elaine Kilgour, Kathryn L. Simpson, Dominic G. Rothwell, David A. Moore, Kristopher K. Frese, Melanie Galvin, Angela Lamarca, Richard A. Hubner, Juan W. Valle, Mairéad G. McNamara, Caroline Dive. Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine CarcinomaClinical Cancer Research 2022; 28(10): 1999 doi: 10.1158/1078-0432.CCR-21-3058
21
Li Chen, Shaolong Huang, Qiang Liu, Xiangyi Kong, Zhaohui Su, Mengliu Zhu, Yi Fang, Lin Zhang, Xingrui Li, Jing Wang. PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant ChemotherapyFrontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.849468